CJC-1295 (no DAC) + Ipamorelin: research background
What these Compounds Are
CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH) (PMID 16352683). Therapeutic peptides like CJC-1295 and ipamorelin are short chains of amino acids that regulate cellular functions and facilitate biochemical processes (PMID 41476424). Both CJC-1295 and ipamorelin are classified as growth hormone secretagogues (PMID 41490200, PMID 42021992).
How They Are Thought to Work
Growth hormone secretagogues, including ipamorelin and CJC-1295, are known to activate IGF-1 signaling (a pathway involving insulin-like growth factor 1) and support satellite cell repair (PMID 41490200). CJC-1295 functions by stimulating the secretion of growth hormone (GH) (PMID 16352683). The use of these peptides in gerontology targets fundamental hallmarks of aging, including hormonal decline (PMID 42021992).
What Laboratory and Animal Studies Report
In murine (mouse) models with glucocorticoid-induced muscle loss, CJC-1295 combined with ipamorelin significantly improved maximum tetanic tension (animal study, PMID 41476424). Many unapproved peptides, including CJC-1295 and ipamorelin, have shown favorable tissue repair and metabolic outcomes in animal models (animal study, PMID 41966639). Preclinical animal models, most commonly rats, have shown that peptides like CJC-1295 and ipamorelin demonstrate unique mechanisms with promising, but variable, effects on tendon, muscle, bone, and ligament healing (animal study, PMID 42578445).
Human Evidence So Far
In healthy adult human subjects (ages 21-61 years), a single subcutaneous injection of CJC-1295 resulted in dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more, and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days (human study, PMID 16352683). The estimated half-life of CJC-1295 was 5.8-8.1 days. After multiple doses, mean IGF-I levels remained above baseline for up to 28 days (human study, PMID 16352683). The administration of CJC-1295 was reported to be safe and relatively well tolerated, particularly at doses of 30 or 60 µg/kg in healthy adults, with no serious adverse reactions reported (human study, PMID 16352683). There was evidence of a cumulative effect after multiple doses (human study, PMID 16352683). Online forum users discussing female use of CJC-1295 mentioned reasons including weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing (human user reports/netnography, PMID 26771670).
Open Questions and Limitations
While preclinical studies show promise for these therapeutic peptides, there is currently a lack of rigorous human clinical trials for many of these compounds in orthopedics (PMID 41490200). The findings from animal studies for CJC-1295 combined with ipamorelin are limited to animal models and are largely unvalidated in human trials for musculoskeletal applications (PMID 41476424). Rigorous human safety data for many unapproved peptides, including CJC-1295 and ipamorelin, are scarce, and there is potential for serious harm to patients (PMID 41966639). Human clinical studies involving these peptides are limited, often lacking robust controls or rigorous study designs, and human data are heterogeneous, showing modest improvements at best for metabolic bone health and degenerative knee pain (PMID 42578445). Significant knowledge gaps exist regarding optimal dosing regimens, effects of combination therapy, and biomarkers for monitoring efficacy (PMID 42021992).
Key Terms Explained
Growth hormone-releasing hormone (GHRH): A hormone that stimulates the release of growth hormone from the pituitary gland (PMID 16352683). Growth hormone (GH): A hormone that promotes growth and cell reproduction (PMID 16352683). Insulin-like growth factor I (IGF-I): A protein with a similar molecular structure to insulin that plays an important role in childhood growth and continues to have anabolic effects in adults (PMID 16352683). Growth hormone secretagogues: Substances that stimulate the secretion of growth hormone (PMID 41490200). Satellite cell repair: A process involving specialized cells that help in muscle regeneration and repair (PMID 41490200). Tetanic tension: The maximum sustained contraction force that a muscle can produce (PMID 41476424).
Studies cited in this section
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. — The Journal of clinical endocrinology and metabolism, 2006 (PMID 16352683)
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026 (PMID 41490200)
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine, 2026 (PMID 41476424)
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.), 2026 (PMID 41966639)
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine. — The American journal of sports medicine, 2026 (PMID 42578445)
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. — Substance use & misuse, 2016 (PMID 26771670)
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. — Frontiers in aging, 2026 (PMID 42021992)
Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
